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Abstract 
In this Review, I present evidence supporting a multi-factorial causation of childhood acute 
lymphoblastic leukaemia (ALL), a major subtype of paediatric cancer. ALL evolves in two 
discrete steps. First, in utero initiation by fusion gene formation or hyperdiploidy generates a 
covert, pre-leukaemic clone. Second, in a small fraction of these cases, the post-natal 
acquisition of secondary genetic changes (primarily V(D)J recombination-activating protein 
(RAG) and activation-induced cytidine deaminase (AID)-driven copy number alterationsin the 
case of ETV6-RUNX1+ ALL) drives conversion to overt leukaemia. Epidemiological and 
modelling studies endorse a dual role for common infections. Microbial exposures earlier in 
life are protective but, in their absence, later infections trigger the critical secondary mutations. 
Risk is further modified by inherited genetics, chance and, probably, diet. Childhood ALL can 
be viewed as a paradoxical consequence of progress in modern societies where behavioural 
changes have restrained early microbial exposure. This engenders an evolutionary mismatch 
between historical adaptations of the immune system and contemporary lifestyles. Childhood 
ALL may be a preventable cancer. 
 
[H1] Introduction  
Childhood acute leukaemia is the most common paediatric cancer in developed societies, 
accounting for one third of all cases with a variable incidence rate of 10–45 cases per 106 
children per year and a cumulative risk of ~1 in 2000 up to the age of 15 years 1. The most 
common paediatric leukaemia, acute lymphoblastic leukaemia (ALL), is an intrinsically lethal 
cancer, as evidenced by a universally adverse clinical outcome before effective therapy was 
developed 2. Currently, however, cure rates for ALL using combination chemotherapy are 
around 90% 3, making this one of the real success stories of oncology.  
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 Whilst this is a cause for celebration, the current treatment remains toxic, traumatic for 
young patients and their families and with some long term health consequences 4,5. It is 
unfortunate that we have remained ignorant as to the cause of ALL. The open question as to 
whether this cancer is potentially preventable is therefore important. 
Environmental exposures possibly linked to ALL are legion 6 but in many cases these 
associations are weak, inconsistent or lacking in biological plausibility 7. Large and multi-
disciplinary nationwide studies or international consortia 8,9 have provided a more enabling 
framework for addressing this question but, to date, the only accepted causal agent for ALL, 
albeit under exceptional circumstances, is ionising radiation 10-12. The causes of ALL might 
best be understood by using biological insights into the cancer itself as the foundation for 
designing, testing and validating hypotheses.  
 Childhood ALL includes a number of subtypes defined by cell lineage (B or T), 
differentiation status and genetics (Fig 1a). These differ by age distribution (Fig 1b), clinical 
outcome (see Fig 1 legend) and could have distinctive aetiologies. In this Review, I focus on 
the body of evidence – epidemiological, biological and genetic, that has accumulated, 
particularly over the past decade, supporting a causal mechanism that is selective for the 
common, or B cell precursor, subtype of childhood ALL (designated here as BCP-ALL) 7. This 
is suggested to be a multi-factorial mix of infectious exposure, inherited or constitutive genetics 
plus chance, with patterns or timing of common infection in early life identified as the critical 
component and a potential route for preventative intervention. 
 
[H1] Infection hypotheses 
The idea that infections might play a causal role in childhood ALL is around 100 years old 13. 
When it became clear that leukaemia in a number of animal species – chickens, mice, cattle 
and cats, were viral in origin 14, there was an expectation that a similar transforming virus might 
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be responsible for childhood ALL, as well as for other blood cell cancers. To date, all attempts 
to molecularly identify or otherwise incriminate a leukaemogenic virus in ALL have failed 7. 
 In 1988, two hypotheses were presented that suggested a new perspective on this 
problem. The two models are sometimes considered as alternative or competing explanations. 
I believe they portray the same picture, through different lenses. Both propose that childhood 
leukaemia may arise as a consequence of an abnormal immune response to common 
infection(s). One model, advanced by epidemiologist Leo Kinlen, was based on transient and 
localised increases in the incidence of childhood leukaemia that could be ascribed, 
epidemiologically, to population mixing 15,16 (Box 1). 
 The other model that I proposed was dubbed the ‘delayed infection’ hypothesis, the 
focus of this article, and was more biological than epidemiological in its origins and was 
applied specifically to BCP-ALL 7,17. Central to this were two propositions.  
First, that the immune system, in both its innate and adaptive arms, had evolved to both 
anticipate and require microbial infectious exposure peri-natally or in infancy 18. The dynamics 
and composition of the microbiome and virome of infants is highly variable 19 and early, 
microbial exposures have lasting impacts on immune function and health 20,21. Metabolites of 
commensal bacteria promote regulatory T cells and impact on subsequent inflammatory 
signalling pathways 22. Deficits of this ‘natural’ microbial experience, especially in modern 
societies, result in an unmodulated or distorted immune network 23.  
A consequence of an under-exposed immune network in infancy was predicted to be 
subsequent dysregulated responses to common infections that could promote or trigger BCP-
ALL. The increased incidence in childhood ALL in developed societies was therefore 
considered to be a paradox of progress, and the link to infection inverted: the problem might 
be lack of infection. An equivalent mismatch of evolutionary adaptations and modern lifestyles 
may underlie the causation of several common adult cancers in the developed world 24. 
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The second proposition related to the natural history of the disease. The speculation 
was that ALL most likely developed by two critical steps: first, an initiating event in utero and 
second, a post-natal mutational event that promotes clinical leukaemia development. The 
prediction was then that an abnormal immune response to infection(s) indirectly triggered the 
requisite secondary mutational events. No specific infection was proposed in relation to either 
protection in early life or post-natal promotion and the immunological mechanism was 
considered to be indirect and therefore not akin to a transforming virus. 
Common infections were therefore proposed to have two opposing impacts on risk of 
ALL, depending upon timing – antagonistic (early) or promotional (late). A parallel would be 
with the divergent roles of microbial infections and chronic inflammation in gastro-intestinal 
and other common cancers in adults 25,26. 
 
[H1] The two-hit model of childhood ALL  
With a few informative exceptions (Supplementary Information S1 (Box)), ALL has a 
clinically silent natural history prior to diagnosis. My colleagues and I developed three different 
tactics for back-tracking the origins of this covert process to before birth. These exploited the 
fact that common fusion genes in ALL (e.g. ETV6-RUNX1 (also known as TEL-AML1), MLL-
AF4 (also known as KMT2A-AFF1, BCR-ABL1) have uniquely variable or idiosyncratic 
breakpoints within the intronic, breakpoint cluster regions of the two partner fusion genes 
involved. The genomic sequences at the gene fusion junction provide stable, sensitive and 
clone-specific markers 27,28. 
 
[H2] Comparative genomics of concordant ALL in monozygotic twins 
Studies on monozygotic twins have been especially informative 29. The possibility that 
concordance of leukaemia in identical twins might be attributable, not to co-inheritance of 
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genetic susceptibility, but to an in utero origin in one twin was first proposed in 1962 30 and 
elaborated on in 1971 31. This idea was based on prior understanding that monochorionic or 
single placentas have vascular anastomoses permitting twin-twin blood transfusion with 
consequent blood cell chimaerism 32. 
The prediction was then that ALL in both twins  should arise in one twin but be 
monoclonal. Unambiguous evidence that this was the case derived from the finding of identical, 
but non-constitutive, clone-specific fusion gene breakpoints and sequences in a series of twin 
pairs 29,33 (Fig 2). That evidence is strengthened by the observation of shared, clone-specific 
immunoglobulin heavy chain (IGH) diversity-joining (DJ) or variable-diversity-joining 
(V(D)J) genomic sequences of concordant BCP-ALL in twins 34.  
 With further exploration of ALL genomes in twins, it has become clear that whilst cases 
with concordant ALL share the identical and singular fusion gene event, other genetic 
alterations present, including copy number alterations (CNAs) and single nucleotide variants 
(SNVs), were different in twin pairs 35,36 (Fig 2). This then suggested that such distinctive 
mutational events reflected independent and divergent sub-clonal evolution, post-natally. 
Similarly, the majority of ongoing V(D)J rearrangements in IGH are sub-clonal and distinctive 
in twin pairs 34. In one twin pair with concordant ETV6-RUNX1+ ALL, whole genome 
sequencing revealed that the fusion gene was the only shared or clonal genetic lesion 37. These 
data endorsed the likelihood that ETV6-RUNX1 fusion was an initiating event or founder 
mutation for ALL. 
 The concordance rate in monozygotic twins varies according to age and ALL subtype. 
In infants (<18 months) with pro-B ALL and MLL fusions, the rate approximates to 100% for 
those with a monochorionic or single placenta 29. This suggested that MLL fusion driven 
leukaemogenesis in such infants was essentially completed in utero and that the fusion gene, 
or a single mutation, was sufficient for leukaemogenesis. Subsequent genomic sequencing of 
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such cases is compatible with this possibility even though other sub-clonal mutations, in RAS 
family genes for example, do occur 38,39. 
 
[H2] Pre-leukaemic clones in healthy co-twins 
The concordance rate in older children with BCP-ALL was calculated to be around 10-15%, 
lower than that in infants 29. A prediction for those pairs of twins with a monochorionic 
placenta, where only one twin develops ALL, is that the healthy co-twin should have a 
population of covert pre-leukaemic cells harbouring the same initiating lesion as his/her co-
twin with ALL, i.e. the twins are discordant for the critical post-natal secondary, genetic event. 
This has been confirmed in three twin pairs with BCP-ALL with hyperdiploidy 40, BCR-ABL1 
fusion 36 or ETV6-RUNX1 fusion 35,41. In this context, the healthy co-twin provides a rare 
‘experiment of nature’ and unique access to the pre-leukaemic clone. Putative pre-leukaemic 
cells from the blood of one healthy co-twin and propagation in vitro and in vivo (in NOD/SCID 
mice) established that these cells have both self-renewal capacity and intact B cell 
differentiation capacity 41, features commensurate with a pre-leukaemic status. Equivalent pre-
leukaemic stem cells for acute myeloid leukaemia (AML) have now been identified in patients 
with AML 42 and normal adults 43. 
 
[H2] Backtracking early genetic events in ALL to neonatal blood spots 
Less than 1% of childhood BCP-ALL cases occur in twins. However, ALL in twins is no 
different, in its biological and clinical features or age incidence, to that in singletons. This 
suggests that many or most childhood ALL cases in singletons might also be initiated in utero. 
 To validate this proposition, my colleagues and I exploited the fact that neonatal blood 
spots, or Guthrie cards, contain reasonably intact DNA. Archived blood spots from patients 
with ALL were screened for clone-specific fusion gene sequences identified at diagnosis. This 
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was first carried out in three cases of infant ALL with MLL-AF4 fusion and blood spots from 
all three cases evaluated were positive 44. Subsequent studies with samples from children with 
ETV6-RUNX1+ ALL found that around 75% were positive 45. These results have been 
independently confirmed 46,47. Negative blood spot results are uninterpretable as this could 
reflect either a post-natal origin or an inadequate number of leukaemic cells in the sample. The 
conclusion drawn from these screens was therefore that the majority of childhood ALL cases 
were pre-natal in origin, though possibly not all. 
 The twin and blood spot studies also provided insight into persistence of pre-leukaemic 
stem cells and post-natal latency in ALL. The oldest twin with concordant ALL originating in 
utero was 14 years at diagnosis, her twin sibling having been diagnosed with ALL some nine 
years earlier 48. The oldest non-twin case with ALL and a positive neonatal blood spot to date 
was diagnosed at 9 years, 4 months old 49. 
 
[H2] Frequency of ALL initiation in utero 
The data on discordant, monozygotic twins suggested that some or possibly most individuals 
harbouring a pre-natally generated, covert pre-leukaemic clone never progress to overt ALL. 
This begs the important question, relevant to aetiology, of the frequency of initiation of ALL 
in utero and the frequency of its transition to overt leukaemia. 
To address this issue, my colleagues and I screened a large cohort of unselected cord 
blood samples for ETV6-RUNX1 fusion mRNA (data summarised in Supplementary 
Information S2 (Fig)). The striking result was that approximately 1% of newborns (6/567) had 
a covert and modest sized, putative pre-leukaemic population at around 10-4 of B lineage cells 
50. This result, initially challenged 51, has been independently confirmed 52-54. A ~1% incidence 
for ETV6-RUNX1 in relation to incidence of the leukaemia itself reflects a low transition 
probability of around 1% with 99% of pre-leukaemic clones initiated during foetal 
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development never progressing to clinical ALL. This low transition probability could reflect 
either lack of persistence of the pre-leukaemic stem cells after birth or a severe bottleneck in 
acquisition of the necessary secondary genetic changes. 
These data suggest that initiation of leukaemia in utero may be far more common than 
indicated by the incidence of disease, with implications for causation. The same may apply to 
some other paediatric cancers. Histological evidence and some genetic data suggest that the 
frequency of precursor lesions for neuroblastoma 55 and Wilms tumour 56 may also be some 
100 times the incidence of clinical cancer 50. 
 
[H2] Other subtypes of ALL 
These lines of investigation were pursued using fusion genes as the predominant clonal markers 
of early genetic events in ALL. The most frequent subtype of BCP-ALL  is, however, 
characterised by chromosomal hyperdiploidy, which is harder to track than fusion genes. There 
is evidence however that the key findings described above for the ETV6-RUNX1 subset are 
likely to apply to hyperdiploid ALL. Monozygotic, monochorionic twin pairs concordant for 
hyperdiploid ALL are described with identical karyotypes 40 and neonatal blood spots of 
children with hyperdiploid ALL have clone-specific IGH sequences 57-59. In one case of 
hyperdiploid ALL, the child’s cord blood had been frozen at birth. Retrieval of this sample led 
to the identification of putative pre-leukaemic cells in the cord blood with the same triploid 
chromosomes as in the child’s subsequent ALL 60. Hyperdiploidy, generated by a one-off 
abnormal mitosis resulting in trisomies 61, can therefore occur in utero as an alternative 
initiating event to gene fusion for BCP-ALL.  
[H1] Further genomic exploration of ALL 
Whole genome sequencing of a cohort of 57 cases of ETV6-RUNX1+ BCP-ALL  provided an 
audit of all mutational changes 62. This confirmed the previous finding  that the most common 
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recurrent events were CNAs, primarily gene deletions 63. SNVs were also present but with low 
or undetectable recurrency62 Genomic sequencing in cancer can reveal mutational signatures 
of relevance to aetiology 64. Almost 50% of CNAs in ETV6-RUNX1+ BCP-ALL had partial or 
complete V(D)J recombination-activating protein (RAG) heptamer-nonamer recognition 
motifs within 20 base pairs of the breakpoints 62. This finding may explain the observation that 
highly recurrent CNAs in BCP-ALL are reiteratively present in subclones of individual patients 
65,66. A comparison with CNAs in around 14,000 cases of breast, prostate and pancreatic cancer 
revealed none with RAG motifs 62. SNVs in ETV6-RUNX1+ BCP-ALL had two main mutated 
signatures: one was C>T transitions at CpGs and C>G and C>T mutations at TpCs, and a 
second was transitions and transversions in a TpC context at NpCpG trinucleotides 62. These 
second signatures are very common in cancer generally reflecting APOBEC cytidine 
deaminase activity 64,67. 
 These genomic studies indicate that BCP-ALL has very restricted but informative 
mutational signatures and a low level of background or neutral genetic alterations 62. This 
makes it less likely that BCP-ALL is caused by genotoxic exposures, which generally 
precipitate more widespread genomic instability with multiple distinctive signatures 64. 
The other genetic subtype of BCP-ALL – hyperdiploid ALL, also has recurrent CNAs 
that may be RAG-mediated in genes including PAX5, IKZF1 and ETV6. In contrast to ETV6-
RUNX1+ ALL however, hyperdiploid ALL have recurrent mutations in receptor tyrosine kinase 
(RTK)-RAS pathways and histone modifiers  61,63. 
Collectively, these data provide a firm cellular, genetic and mechanistic framework for 
the two step model for BCP-ALL and highlight both critical time windows, pre- and post-
natally, and mutational mechanisms. Any proposed causative mechanism in ALL should 
accommodate this natural history profile. The initiating role of ETV6-RUNX1 and the 
postulated sequence of events in ALL is endorsed by modelling within both human and animal 
11 
 
cells (Box 2 and further below). The timing and tissue site of B cell precursor ALL initiated by 
ETV6-RUNX1 or hyperdiploidy in utero is uncertain but may involve transformation of a 
unique, foetal liver progenitor cell (Box 3). 
 
[H1] Inherited susceptibility 
Childhood ALL only very rarely runs in families but this observation may underplay inherited 
genetic risk since the disease itself is rare. Twin concordance is unhelpful in this respect since 
the risk has a mostly non-genetic basis – blood cell chimaerism in utero. The risk of ALL in 
non-identical twins is unknown but sibling risk has been estimated to be around 3.0x compared 
to the risk in the general population, which provides evidence of a modest but definite 
contribution of constitutive, genetic variation to risk 68. 
 Earlier, targeted gene screening approaches suggested that inherited allelic variants 
encoding proteins involved in DNA repair, carcinogen metabolism or the folic acid pathway 
might be linked to risk of childhood ALL 69,70. Unfortunately most of these studies were under-
powered to detect small effects or have not been consistently replicated, so their significance 
remains uncertain 70. 
 Genome wide association studies (GWAS) have provided unambiguous evidence for 
multiple gene variants impacting on risk of ALL (Table 1) 70,71. The individual alleles described 
to date have a significant but relatively modest impact (see odds ratio in Table 1) and appear 
to be additive rather than synergistic, functionally. The functional logic of these associations is 
unclear but as most of the relevant single nucleotide polymorphisms (SNPs) lie outside coding 
regions, they are likely to be regulatory, impacting on levels of protein 72,73. 
 It is striking that in ALL, as in many other cancers, most of the candidate risk genes 
implicated in GWAS (Table 1) are the same genes that have acquired (non-constitutive) 
mutations in the same cancer type. One interpretation of this is that the inherited allelic variants 
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interact functionally (or epistatically) with the mutated alleles to increase vulnerability of cells 
to transformation. A low functioning inherited allele for example would render a deletion in 
the other allele functionally homozygous with a potentially increased impact on cellular fitness. 
A prediction that follows from this is that there should be a preferential loss, by deletion, of the 
non-risk allele (in heterozygotes for that allele) as only that deletion would increase clonal 
fitness. Evidence for this has been presented with respect to risk variants of CDKN2A 74,75. 
However, for ARID5B there is preferential gain of the risk allele (via trisomy 10) in 
heterozygotes 72. 
 To date GWAS have provided no evidence implicating immune response gene variants, 
as might have been anticipated from infection-based hypotheses for the aetiology of ALL. 
However, prior studies examining major histocompatibility complex (HLA) genes 76-78, 
interferon- (IFNG) 79, Toll-like receptor 6 (TLR6) 80 or the presence and/or absence of specific 
killer-cell immunoglobulin-like receptor (KIR) family genes 81 did record significant 
associations with particular allelic variants. Notably, TLR6 variants and KIR genes were 
associated with decreased risk of all childhood ALL. It remains unclear if the large GWAS 
multi-cohort studies invalidate these data or whether the SNP screens in GWAS adequately 
detect the relevant variants. This is an important discrepancy to resolve. 
 Childhood ALL can also arise in a rare familial syndrome context with inherited 
mutations in genes also implicated as acquired mutations in leukaemia including PAX5 82 and 
ETV6 83. The relatively infrequent low hypodiploid subset of BCP-ALL is strongly associated 
with inherited TP53 mutations or Li Fraumeni syndrome 84. Further rare risk alleles, but with 
intermediate to high penetrance, are likely to be uncovered in ongoing, large scale studies. 
Children with Downs syndrome have an approximately 20-30 fold increased risk of BCP-ALL 
85. Trisomy 21 in Downs syndrome is associated with over-expression of a nucleosome 
remodelling protein HMGN1 and enhanced self-renewal of B cell progenitors 86. In patients 
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with ALL, this is complimented by secondary genetic changes including in CLRF2, JAK2, 
NRAS and KRAS 85. All told, however, familial syndromes and Downs-associated ALL are 
likely to account for only a small fraction of cases of childhood ALL. 
 The general conclusion to be drawn from these genetic studies is that inherited 
susceptibility does contribute to risk of BCP-ALL. The attributable risk or quantitative 
contribution is, however, unclear. A sibling risk of three fold for ALL, seen against a 
background risk of 1:2000, suggest the genetic component, though real, is minor; at least 
compared to some other common adults cancers (prostate, breast) 87. On the other hand, there 
could be a complex interplay between genes and environmental exposures 73,88 in which genetic 
background makes a more substantial difference. This has yet to be fully explored. 
 
[H1] Possible causes of initiating events No epidemiological studies to date have clearly 
implicated exposures during pregnancy, linked to risk of ALL, that might explain how the 
initiating mutations for BCP-ALL arise. ETV6-RUNX1+ BCP-ALL has no mutational 
signatures that might implicate any particular type of aetiological exposure. There is no 
evidence for RAG involvement but, in common with IGH rearrangements 89, the recombination 
event appears to involve non-homologous end joining via micro-homologies 27. 
 If around 1% of unselected newborns have an in frame ETV6-RUNX1 fusion in an 
expanded clone derived from the appropriate cell type for BCP-ALL (B lineage progenitor), 
then considerably more newborns should have acquired this or other fusion genes in the wrong 
cell types or out of frame for a functional protein. It therefore seems likely that whatever causes 
this genetic alteration, it could be very common or possibly ubiquitous. 
 The original proposition 17 was that ALL was initiated, in utero, by a spontaneous 
mutation, or with no external exposure involvement. Developmental, endogenous factors such 
as proliferative and oxidative stress or the profound apoptotic signalling in early lymphopoiesis 
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could be involved. Spontaneous mutations or mutations caused by endogenous processes are 
common during foetal development 90. Endogenously-driven double-strand breaks, required 
for fusion gene recombinants, occur at around 50 per cell cycle in human cells 91. It has been 
suggested that most paediatric cancers arise during embryonic or foetal life and can similarly 
be considered as developmental errors 92. In the absence of evidence to the contrary, this 
remains the most plausible explanation for initiation of BCP-ALL  and focuses attention on the 
post-natal triggering of promotional events which are required for clinical disease. There is 
clearly scope for more research on the origins and mechanisms involved in fusion gene 
formation, and hyperdiploidy, in utero. 
 
[H1] Epidemiological evidence 
Epidemiological evidence suggests that patterns of infection after birth have a causal role in 
triggering ALL. The ‘delayed infection’ hypothesis lends itself to epidemiological evaluation 
in a case-control setting. A prediction of the model was that common infections in infancy 
should be protective against BCP-ALL. There is no prior reason to implicate any particular 
infectious agent (eg, bacteria, virus or parasite),and the relevant infections need not be 
symptomatic or pathological. A longstanding need for microbial, immune network modulation 
might reflect common, commensal, or ‘old friends’ organisms, such as gut microbiota, soil 
mycobacteria or helminth parasites 93. In this context, a surrogate of overall infectious exposure 
during infancy could be considered an appropriate variable. Quantifiable surrogates include 
social exposures of infants in the home, related to the number of siblings and birth order, or in 
day care centres, and breast feeding. These variables have been investigated in epidemiological 
case/control or cohort studies for risk associations with ALL overall and, in some instances, 
selectively for the major BCP-ALL subset. 
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[H2] Impact of day care attendance in infancy 
In the 1990’s, the UK Children’s Cancer Study Group (UKCCS) was set up to test the delayed 
infection hypothesis, in a case-control context, in addition to an analysis of other exposures 
including ionising and non-ionising (EMF) radiation and chemicals 8. Day care attendance was 
chosen as one surrogate for infectious exposure since this was well documented as a context 
for enhanced social contacts facilitating spread of common infections 94. The UKCCS involved 
almost 1300 cases of ALL (all subtypes) and over 6000 matched controls. Although only a 
relatively small number of controls experienced day care in the first twelve months of life, the 
data showed a significant protective impact on risk of ALL overall and on BCP-ALL 95. 
 This association has been documented in additional studies in California 96, Scandinavia 
97, France 98 and an international consortium 99, and has been endorsed by a meta-analysis 100. 
The meta-analysis noted significant, between study heterogeneity and one early, large scale 
study failed to detect any impact of day care on risk of ALL 101. No protection is afforded 
against childhood AML by day care attendance or, to date, any other paediatric cancer, which 
increases confidence that the associations seen in ALL was not confounded by social or other 
variables. 
 It was anticipated that assessing, in a case-control fashion, actual infections in infancy 
would be informative. This however is fraught with difficulties and has provided mixed results. 
Parental recall is known to be suspect or inaccurate in this respect 102. Medical records are more 
reliable, particularly in the UK with nationwide registration of children with general 
practitioners (GPs) and a free health service. One such analysis found more, rather than less, 
infections reported for children who subsequently developed ALL, compared with controls 102. 
The main difficulty here, other than possible bias in use of GP services, is that we do not know 
if the relevant ‘modulating’ infectious exposures in infancy are necessarily symptomatic; they 
might well not be. In this sense the surrogate of day care could be considered preferable. 
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Several studies have however reported, in accord with the hypothesis, an inverse relationship 
between common infections in early life, including inner ear infections, and risk of ALL 
98,101,103-106. 
 
[H2] Birth order and risk of ALL 
A further surrogate measure of infectious exposures in infancy is the number of siblings 
cohabiting and, in particular, birth order. The prediction was that first-borns would be more at 
risk compared to later-borns who would, as infants, benefit from protective exposures via older 
siblings. One large UK-based study (>3000 cases of ALL and the same number of matched 
controls) found a striking association of birth order with risk for ALL, but not for AML 107. 
Other case-control studies in France 98 and California 100 also found a significantly increased 
risk for first (versus third) born children, as does a recent international cohort analysis (Ora 
Paltiel; personal communication 2018)  
 If natural infections early in life reduce risk of ALL, then it might be expected that some 
vaccinations would have an effect. The data on vaccination histories have produced null or 
inconsistent results. However, there is one exception: immunisation against Haemophilus 
influenzae B in infancy appears to confer a degree of protection against ALL 108. 
 If the ‘natural’ microbiota is part of a longstanding and critical interaction with the 
developing immune system, then antibiotic use in infancy might increase risk of ALL. This has 
not been systematically evaluated to date, though an earlier report from China did suggest an 
increased risk associated with exposure to chloramphenicol 109. 
 
[H2] Mode of delivery, breastfeeding and risk of ALL 
Mode of delivery at birth influences the early exposure of newborns to benign microbiota 110, 
as caesarean delivery deprives newborns of the microbial exposures associated with vaginal 
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passage. Cohort and case/control studies have reported a significantly increased risk of ALL 
associated with caesarean delivery 111-114. No such increased risk was observed for brain cancer 
or lymphoma 111. 
 Breastfeeding during infancy provides nutritional support, maternal antibodies, anti-
inflammatory molecules, some maternal cells, microbes (lactobacilli) and oligosaccharides that 
nourish the infant’s intestinal microbiome (bifidobacteria) 115. It might be anticipated that 
prolonged breastfeeding would have a modulating effect on the immune system of infants and 
reduce risk of ALL. Seventeen case/control studies of the impact of breastfeeding on ALL risk 
have been published 116. In the largest of these, from the USA 117 and UK 118, there was a 
reduced risk for ALL (10-20%) associated with breastfeeding of six months or more. Five 
meta-analyses have now been published with concordant conclusions and the latest of these 
indicated a reduced ALL risk of around 20% for breastfeeding of six months or more 116. 
[H2] Clusters of ALL 
Although no specific microbial agent or a unique transforming virus is suspected in ALL, there 
might be one circumstance where a single type of infection is involved. This is in the very rare 
cases of space-time clusters. A prediction of our hypothesis would be that a single cluster of 
cases might be associated with a single infection or microbe species but independent, 
space/time clusters could involve different infectious triggers. 
 Many putative clusters of childhood leukaemia have been reported but two stand out. 
The first was in of Niles, a suburb of Chicago in 1957-60 – where there were eight cases 
(relative risk (R.R.) 4.3) diagnosed as ALL or ‘stem cell’ leukaemia 119. All patients and/or 
their older siblings attended the same school. The second cluster involved 13 cases of BCP-
ALL over four years (2000-2004; R.R. = 12.0), but ten cases in just ten months in 2001 in the 
small town of Fallon, Nevada 120. 
18 
 
A neglected aspect of these two clusters is that the cases, though resident in the cluster 
area at the time of diagnosis, were mostly born outside of that area 7. Plus the clusters involved 
children diagnosed with ALL at different ages (2-11 years) and a narrow time frame of 
diagnoses. Given what we now know of the natural history of ALL, these data then indicate 
any causal exposure, linked to the cluster, would have to be proximal in time to diagnosis 
(rather than pre-natal) and therefore promotional. The Niles cluster was linked, observationally, 
to an outbreak of streptococcal fever 119. The cause(s) of the Fallon cluster of ALL remain 
unresolved and contentious though a possible role of adenovirus was hypothesized 120. 
 A significant  space-time cluster of BCP-ALL in Milan has recently been recorded 121. 
Seven cases were diagnosed in a four week period; four of these lived within one small 
residential area and three of these four attended a single school. The Kulldorff scan method 122 
identified this as a significant space/time cluster (p = 0.017) Given the narrow time window of 
the diagnoses (four weeks) and the age range of the cases (2-11 years), any causal exposure, as 
in Niles and Fallon, would be proximal to diagnosis, promoting overt ALL evolution from a 
prior and covert pre-leukaemic state. The Milan cases sparked substantial public anxiety, 
particularly in relation to the school, and a detailed epidemiological investigation was 
launched. No link was found with ionising radiation, non-ionising radiation or chemicals. There 
was, however, an association with a particular, common infection. All seven cases had been 
infected with endemic AH1N1 swine flu virus during the epidemic that preceded the ALL 
cluster by three to six months. The infection frequency in children in Milan during the same 
period was relatively high, at around one third, but this still indicated the link with cases was 
significantly different from expected (p = 0.01) 121. Six of the seven cases were first born and 
none attended day care in the first year of life. 
Proof of a causal role for infections in these situations is not possible and clustering of 
cases by chance cannot be excluded. But the observations accord with predictions of the 
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infection hypothesis and highlight that influenza viruses are potential promoting agents for 
ALL. A prior study in the UK observed peaks in incidence of childhood ALL ~6 months after 
seasonal influenza epidemics 123. A final piece of epidemiological evidence indirectly 
supporting a role of common infection in childhood ALL comes from anecdotal but striking 
observations on rapid changes in the incidence of ALL that were preceded by major social 
changes in Germany and Hong Kong  (Supplementary Information S3 (Box)). 
There is no compelling reason for postulating an exclusive role for influenza viruses or 
indeed for viruses. A role for cytomegalovirus (CMV) in ALL has been postulated, but as an 
early, in utero, modulator of immunity, rather than as a proximal trigger 124.  
 In some respects it is surprising that the epidemiological data is as consistent as it is on 
individual factors related to infection in ALL since many variables will compound to influence 
patterns of microbial exposures in early life (Supplementary Information S4 (Box)). 
 
[H1] Modelling the ‘missing link’ in ALL 
There are limits to what epidemiological studies can achieve and to the robustness of the 
findings. Nevertheless, the associations described are compatible with the infection model 
proposed and their selectivity for BCP-ALL, versus AML, is striking. But associations are not 
necessarily causal. Functional components of the infection hypothesis are best addressed by 
modelling studies in mice (Box 2). These have proven very informative. One inflammatory 
cytokine - TGF, was found to induce preferential expansion of ETV6-RUNX1-driven pre-
leukaemic cells of both mouse and human origin 125. Normal B cell precursor proliferation is 
inhibited by TGF via activation of the cell cycle inhibitor p27. ETV6-RUNX1 blocks this 
activity giving pre-leukaemic cells a fitness advantage in the presence of TGF 125. 
 The missing link in the chain of events between infection, inflammatory responses and 
promotion of BCP-ALL may be activation-induced cytidine deaminase (AID) 126,127. As noted 
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above, genomic sequencing in BCP-ALL revealed that the recurrent CNAs  have signatures of 
RAG activity 62. Physiological RAG activity in germinal centre Ig class switching or 
hypermutation requires AID, 128 as does illegitimate recombination between the IGH locus and 
oncogenes 129,130. In B cell precursors, AID is not normally co-expressed with RAGs but is 
inducible by infection-driven cytokine signals 131. This suggested that one route by which 
infection or chronic inflammation might trigger RAG-mediated CNAs and ALL is via 
activation of AID expression in pre-leukaemic stem cells. 
 A mouse model has tested the requirement for RAGs and AID in the transition from 
ETV6-RUNX1 pre-leukaemia to overt ALL 126. The data revealed that lentiviral transfection of 
ETV6-RUNX1 into progenitor cells leads to B cell precursor ALL when those cells are treated 
with a surrogate inflammatory signal (bacterial lipopolysaccharide binding to TLR4) that 
activates AID. Critically, mice did not develop ALL if the same experiment was conducted in 
a RAG1-/- genetic background. More recently, my colleagues and I have screened a series of 
inflammatory cytokines for their ability to trigger AID expression in human B cell precursors. 
The most potent was TGF (V Cazzaniga, AM Ford, M Greaves, unpublished data). TGF is 
known to promote other cancers, often in the context of chronic inflammation 132. In ALL, its 
role may include not only selective expansion of pre-leukaemic cells 125 and activation of AID 
but compromise of natural killer (NK) cell-based immune-surveillance 133. 
 If the aetiological hypothesis is correct, then it should be possible to influence risk or 
penetrance of ALL in murine models by timed exposure of the immune system to natural 
infections. Using a model of BCP-ALL it was shown that ALL developed if Pax5+/- mice were 
switched from a germ-free environment to one providing exposure to common microbial 
pathogens 134. Similarly, another study found that ~10% of mice with ETV6-RUNX1 developed 
BCP-ALL after exposure to common pathogens 135. The experiments provide evidence, albeit 
in murine models, that common infections can have, as predicted, a promotional role in ALL. 
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 Another mouse model has provided evidence that early stimulation of the immune 
system can be protective. Exposure of mice transgenic for E-Ret or E2A-PBX1 to 
oligodeoxynucleotides  (which bind to TLR7, TLR8 and TLR9) at four weeks depleted both 
normal and pre-leukaemic precursors and both delayed and diminished risk of progression to 
ALL 136. This effect was dependent upon IFN. In contrast, binding of polyI:C, a TLR3 ligand 
which does not induce IFN, resulted in an expansion of the pre-leukaemic cell pool. These 
data hint that the nature of infectious exposures in infancy and responses of the innate immune 
system may influence not only subsequent immune responses but the fate of pre-leukaemic 
cells. 
 
 
 
 
[H1] Conclusions: paradoxes of progress 
“We incline on our evidence to the belief that the solution of the problem of leukaemia lies 
rather in some peculiar reaction to infection than in the existence of some specific infective 
agent.” 
F J Poynton, H Thursfield and D Paterson 
(Great Ormond Street Hospital for Sick Children), 1922 137 
 
Collectively, the accumulated evidence derived from epidemiological studies, GWAS, genome 
sequencing, biological scrutiny of the natural history and molecular pathogenesis of BCP-ALL, 
plus mechanistic and modelling studies, provide us with a more substantive and credible 
version of the original 7,17 two hit model for childhood ALL, as summarised in Fig 3. The model 
applies selectively to the common, B cell precursor subset of ALL, although the evidence is, 
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currently, more compelling for the ETV6-RUNX1+ subset of BCP-ALL than for hyperdiploid 
subset. The rarer pro-B ALL in infants appears likely to have a different causation and 
molecular pathogenesis, as does childhood AML and childhood lymphoma. There is 
insufficient data for T-ALL in this respect. Other causal associations in leukaemia and cancer 
in general might be revealed or strengthened by a focus on well-defined subtypes, as suggested 
for breast cancer 138. 
 The causal mechanism proposed here is multifactorial, involving patterns of infection, 
inherited genetics and other modulators of risk including chance and, probably, diet (Box 4). It 
has a logical coherence 139 and is grounded in the fundamental biology of leukaemia and 
evolutionary logic of the immune system network functions. The central thesis posits BCP-
ALL as a paradox of progress in developed societies contingent upon a mismatch between the 
historical or evolutionary programming of the immune system and contemporary lifestyles that 
restrain opportunities for early life microbial exposures. Childhood ALL is probably not the 
only unanticipated, deleterious health consequence of diminished infectious exposure in 
infancy 93. Similar epidemiological associations exist for Hodgkin lymphoma in young adults 
140 as well as for childhood allergies and autoimmune disease 141 (Supplementary Information 
S5 (Box)). In all these clinical situations, the common theme is that acquisition of common 
microbial infections in early life has an impact on later responses of the immune system to 
challenge and the subsequent presence or absence of pathology 24,93,142. Diminished exposure 
early in life to microbes that are pathological has been highly beneficial, reducing infant 
mortality, but it seems plausible that a suite of illnesses prevalent now in young people in more 
developed societies, including BCP-ALL, could be due to an unanticipated consequence of this 
advance 93. 
 The infection hypothesis would benefit from further scrutiny including validation and 
extension of the animal modelling but its public health implication is clear. Most cases of 
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childhood ALL are potentially preventable. But how? Promotion of lifestyle changes including 
day care attendance or protracted breastfeeding in the first year of life can be advocated but 
would be difficult to achieve. A more realistic prospect might be to design a prophylactic 
‘vaccine’ that mimics the protective impact of natural infections in infancy, correcting the 
deficit in modern societies. Reconstitution or manipulation of the natural microbiome 143-146 or 
Helminth injections 147,148 are strategies under consideration for early life immune disorders in 
modern societies including autoimmune and allergic conditions. Oral administration of benign 
synbiotics (bacteria species such as lactobacillus and oligosaccharides) can have profound, and 
beneficial, modulating effects on the developing immune system 149. The results of those 
endeavours might inform approaches for preventing BCP-ALL. Cross collaboration of 
scientists working in disparate fields of early life immune dysfunction – allergy, autoimmune 
disease and ALL – would be beneficial. 
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Box 1 
The population mixing hypothesis 
The Kinlen hypothesis 15,16 was prompted by public concerns over apparent increases in 
childhood leukaemia in the vicinity of nuclear power plants in the UK. Kinlen’s model 
proposed that childhood leukaemia was caused by a rare or abnormal reaction to a common 
infection of low pathogenicity in a population at risk because of migration and mixing in the 
context of lack of herd immunity 150. By analogy with animal leukaemias, Kinlen favoured a 
specific virus. The model was also considered to apply across the board to childhood blood cell 
malignancy, irrespective of subtype and was not prescriptive with respect to timing of infection 
in the life of a child. 
The population mixing hypothesis for childhood leukaemia has been explored by 
Kinlen and others in a variety of geographic and demographic settings. The data suggests that 
where an influx of adults and families occurs, particularly into relatively isolated or rural areas, 
a transient increase, in the order of twofold, occurs in incidence rates, compatible with an 
infectious aetiology 16,106,151-153. These studies have not been informative with respect to timing 
of infection in relation to the natural history of disease, the nature of the infection(s) involved 
or mechanistic aspects. Nevertheless, they provide an important tranche of evidence supporting 
a role for common infection(s) in childhood leukaemia. 
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Box 2 
Insights from modelling 
The initiating role of ETV6-RUNX1 in ALL has been modelled in zebra fish 154, mice 155-162 
and with human cells 41. A consensus view is that the ETV6-RUNX1 protein functions as a 
weak oncogene imparting only a modest proliferative or survival advantage on pro-B or pre-B 
cells. This accords with the small clone size of ETV6-RUNX1 pre-leukaemic cells in cord blood 
and in the blood of co-twins of patients with ALL 50. ETV6-RUNX1+ ALL cells ectopically 
express erythropoietin (EPO) receptors and modelling with both human and mouse cells 
suggest that the receptors are functional and that EPO may provide a survival signal to ETV6-
RUNX1-expressing pre-leukaemic cells 163,164. 
The observations on identical twins and cord blood suggest that ETV6-RUNX1 fusion is 
insufficient by itself to induce overt or clinically evident ALL. This is endorsed by the various 
models (see table below). However, as anticipated, ETV6-RUNX1-expressing  clones in mice 
do progress to BCP-ALL if additional, co-operative mutations are introduced by cross-breeding 
with mice heterozygous or homozygous null for the genes recurrently deleted in ETV6-
RUNX1+ ALL, including Cdkn2a and Pax5 161,162. ALL also develops in some of these models 
if mice expressing ETV6-RUNX1 are subjected to insertional mutagenesis 160 or chemical 
exposure 159. 
The impact of these additional genetic lesions that complement ETV6-RUNX1 is to impede or 
block differentiation, mirroring the early B lineage phenotypes observed in the clinical disease. 
This is in accord with the normal function of the transcription factors ETV6 and RUNX1, 
which is primarily to promote differentiation, and their loss of function or deletion in ALL 63. 
This interpretation is further endorsed by modelling studies in which experimental regulation 
of Pax5 expression and gene dosage govern both early B lineage differentiation and 
leukaemogenesis 165. 
 These murine models support the ‘two hit’ hypothesis for BCP-ALL and have also 
provided evidence for the role of common infections in the development of BCP-ALL (table 
below) 134-136. 
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Initiating, transgenic 
lesion 
 
Manipulation Outcome References 
 ETV6-RUNX1 None Covert pre-leukaemia 
only 
 
125,157 
 ETV6-RUNX1 
 
Activation of AID, in vitro, 
with LPS, transplant to 
RAG1+/+ or -/- mice 
 
BCP- ALL  in RAG1+/+  
background 
 
126 
 ETV6-RUNX1 
 
 
 
Switch to non-germ-free 
housing 
 
BCP- ALL 
 
 
135 
 
 
 Pax5+/- Switch to non-germ-free 
housing 
 
BCP- ALL 
 
134 
 E-Ret or 
E2A-PBX1  
 
CpG ODN 
oligodinucleotide (at 4-8 
weeks) 
Delay and reduced 
penetrance of BCP-
ALL 
 
136 
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Box 3 
Is there a unique foetal target cell for childhood BCP-ALL? 
Adults do develop BCP-ALL. But it is striking that hyperdiploid ALL and ETV6-RUNX1+ 
BCP-ALL decline in incidence in teenage years and are infrequent after 20 years of age. Adult 
BCP-ALL has a higher frequency of BCR-ABL1 fusion or a BCR-ABL1-like signalling 
phenotype, perhaps explaining their poorer prognosis 166. Childhood ALL in this respect 
appears to be a different cancer. Why should ETV6-RUNX1 or hyperdiploidy initiate BCP-ALL 
preferentially in early life, and especially in utero? ETV6-RUNX1 expression, driven by the 
endogenous Tel promoter in mice, increases quiescence and persistence of foetal liver stem 
cells 159. Moreover in this mouse model, foetal haemopoietic stem cells expressing ETV6-
RUNX1 had a protracted but still limited lifespan as self-renewing cells and did not contribute 
to the early B cell progenitor pool of adults. This suggests that the low penetrance of pre-
leukaemia in children and the declining incidence of ETV6-RUNX1+ (and hyperdiploid) ALL 
with age may be, at least in part, be due to natural attrition of the foetal pre-leukaemic clone. 
One possibility is that foetal B lymphopoiesis is distinctive, in cell type and/or 
microenvironment, and provides a selective context in which ETV6-RUNX1 and hyperdiploidy 
have effective transforming functions. This appears to be the explanation for GATA1 mutations 
in Downs syndrome-associated acute megakaryoblastic leukaemia (AMKL) being restricted to 
foetal liver 167. Recently a strong candidate target cell for childhood BCP-ALL has been 
identified 168. This cell type is developmentally restricted to foetal lymphopoiesis, with a mixed 
myeloid/B lineage phenotype. In common with the putative target cell suggested by our studies 
in identical twins 34,41, this foetal liver myeloid/B progenitor also has DJ rearrangements of 
IGH 168. 
  
39 
 
Box 4 
Other modulators of risk in childhood ALL 
In addition to patterns of infectious exposure and inherited genetics, other factors are likely to 
contribute to multi-factorial risk including diet and chance. For ALL as well as AML and most 
other paediatric cancers, risk is significantly and consistently elevated in association with 
higher birth weights 169,170 or, possibly, accelerated foetal growth 171. A plausible interpretation 
of this link is that higher weight, possibly orchestrated via IGF1 levels 172,173, may provide 
greater number of cells at risk. IGF1 potentiates expansion of B lineage progenitors 174. 
Recently, evidence has been presented, using mouse models of ALL, that a restricted diet can 
have a risk-reducing impact 175. Intermittent fasting was shown to block expansion of 
leukaemic cell populations and progression of disease. The effect operated via attenuation of 
leptin-receptor expression on leukaemic cells, possibly enforcing differentiation. Diet or 
calorie intake may, therefore, have a modulating impact on risk of ALL, reinforcing the likely 
multi-functional nature of causation of ALL, as in cancer in general. 
Random events or chance get short shrift in cancer epidemiology but it has long been 
recognised that contingency and chance pervades all of biology 176. Some posit that a 
substantial fraction of cancers are due to chance alone 177 but this has been contentious. Chance 
is likely to be an ingredient in each and every cancer including childhood ALL. This is because 
inheritance of risk alleles is a lottery at conception, exposures including infections, at particular 
times, may or may not happen and mutational mechanisms alter genes independently of their 
function 178. 
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Figures 
 
Figure 1a. Immunophenotype screens in the 1970’s and early 1980’s established that ALL 
could be divided into subsets corresponding to early developmental compartments of the B and 
T cell lineages, as indicated in the key Common or B cell precursor ALL (BCP-ALL) is 
genetically diverse (as illustrated) with the two most prevalent alterations being ETV6-RUNX1 
fusion and hyperdiploidy. The rare (~2%) subtype with a mature B cell immunophenotype (and 
frequent IGH-MYC rearrangements) was subsequently recognised (and treated) not as ALL but 
as B lymphoblastic lymphoma. For more detailed descriptions of genomic diversity in ALL, 
see references 179-181.  
41 
 
 
Figure 1b. Age distribution of ALL subtypes from a cohort of 1184 patients with 
ALL entered into MRC-UKALL clinical trials 182 (1975-1984). This pattern of age-associated 
ALL subtypes was validated in a later cohort of MRC-UKALL trials (1991-1996; 1088 patients 
up to 14 years of age) 8 It had been known that childhood ALL had a very marked age incidence 
peak at 2-5 years throughout the developed world. But this peak appeared to be diminished or 
absent in less developed societies and appeared in particular countries and ethnic groups at 
different times 182. Immunophenotypic screens, linked to clinical trials in the UK 183, and an 
international collaborative group study 182 documented that the peak in incidence was 
selectively common or BCP-ALL. Recent epidemiological data indicates that the incidence of 
this subtype of leukaemia in Europe has continued to increase at around 1% per year 184-186. 
This suggested that the increase over time could be real, rather than ascertainment bias, and 
that BCP-ALL might have had a distinctive aetiology. The BCP-ALL subtype was also found 
to have a much more favourable clinical outcome 183,187,188, emphasizing its distinct biology. 
Modified with permission from ref 182. 
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Figure 2. Summary of comparative genomics of ALL in identical twin pairs. The figure is 
based on analysis of 12 monozygotic twin pairs (the number of pairs with each founder lesion 
is noted in parentheses) with concordant ALL 29,33,37,40,48. The sharing of a patient- and clone-
specific fusion gene that is not inherited in the twins indicates that in such cases of concordant 
ALL, the leukaemia must have been initiated in a single cell, in one twin of the pair in utero, 
the clonal progeny of that cell then disseminating to the co-twin, via intra-placental 
anastomoses. In further support of this notion, it was noted that concordance of ALL only 
occurred where the twins shared a single or monochorionic placenta, providing a route for 
cellular transmission 29. Figure adapted from reference 189. CNAs, copy number alterations. 
SNVs, single nucleotide variants. 
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Figure 3. Summary of 2 hit model for role of infections in B cell precursor ALL. 
Genetic, inherited risk alleles are depicted (top of figure) as impacting at any or several stages 
of the step-wise process of ALL.  
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Table 1. Inherited alleles and risk of childhood B cell precursor ALL identified in GWASa 
 
Candidate gene 
(chromosome)b 
 
ALL subset bias Odds ratioc 
(95% CI) 
References 
 IKZF1 
(7p12.2) 
 
None detected 1.69 (1.58 – 1.81) 
1.69 (1.4 – 1.9) 
190 
191 
 ARID5B 
(10q21.2) 
 
Hyperdiploid 1.65 (1.54 – 1.36) 
1.91 (1.6 – 2.2) 
190 
191 
 CDKN2A and  
CDKN2B 
(9p21.3) 
 
None detected 1.36 (1.18 – 1.56) 
1.72 (1.50 – 1.97) 
2.41 (1.99 – 2.92)b 
75 
192 
193 
 
 CEBPE 
(14q11.2) 
 
Hyperdiploid 1.34 (1.22 – 1.45) 
1.45 (1.30 – 1.62) 
190 
194 
 GATA3 
(10p14) 
 
BCR-ABL-like 1.31 (1.21 – 1.41) 
3.85 (2.7 – 5.4) 
195 
196 
 
 PIP 4K2A 
(10p12.2) 
 
None detected 1.40 (1.4 – 1.53) 195 
75 
 
 TP63 
(3q28) 
 
ETV6-RUNX1 0.63 (0.52 – 0.75) 197 
 PTPRJ 
 
ETV6-RUNX1 0.72 (0.68 – 0.89) 197 
 LHBP 
(10q26.13) 
 
None detected 1.20 (1.15 – 1.28) 
 
198 
 ELK3 
(12q23.1) 
 
None detected 1.19 (1.12 – 1.26) 198 
 8q24.1 None detected 1.34 (1.21 – 1.47) 199,200 
 
 2q22.3 ETV6-RUNX1 1.32 (1.17 – 1.49) 199 
 
 IKZF3 
17q12 
None detected 1.18 (1.11 – 1.25) 200 
 
 
a Cohort sizes in these studies were between ~400 and 3500 cases. 
b More low risk alleles are likely to be uncovered as larger cooperative group studies are 
pursued and other populations considered. Rare allelic variants, missed in prior studies, may 
also be identified which have a stronger impact on risk of ALL as described for CDKN2A (OR 
2.4) 193. c p values in these studies were between 10-5 to 10-19. All cases are white, European 
descent in which the alleles exist at relatively high frequency (10-50%). 
